Biotechnology sector-related exchange traded funds are in for a wild ride as Biogen (NasdaqGS: BIIB) is set to receive a verdict from the Food and Drug Administration on its Alzheimer’s drug. Biogen shares are already up 5.8% on Friday ahead of the FDA’s decision. Meanwhile, the VanEck...